Previous close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 3.00 |
Expiry date | 2024-01-19 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
GERMANTOWN, Md., September 26, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the completion of the ENHANCE Pivotal Clinical Study adult cohort following the recently completed 365-day visit for the final study patient.
GERMANTOWN, Md., September 14, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually.
GERMANTOWN, Md., September 11, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into a $50 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The company also announced it drew down $25 million upon the transaction closing.